Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

712

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle Invasive Bladder Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Enfortumab Vedotin
PROCEDURE: Radical Cystectomy

Sponsor

AstraZeneca